5 results about "Methylenedioxy" patented technology

This invention provides an ether-based electrolyte for improving the high-voltage and long-cycle stability of sodium-ion batteries, its preparation method, and its application. The ether-based electrolyte comprises a base electrolyte and additives; the additives include aromatic isocyanates and alkoxysilanes. The aromatic isocyanates are a combination of one of the following: 6-fluoro-1H-1,3-benzodioxane-8-yl isocyanate, 3,4-dihydro-1,5-benzodioxane-7-isocyanate, or 3,4-(methylenedioxy)phenyl isocyanate, and 4-trifluoromethoxyphenyl isocyanate; the alkoxysilanes are 2-cyanoethyltriethoxysilane or 3,3,3-trifluoropropyltriethoxysilane. The electrolyte of this invention achieves synergistic regulation of interfacial reactions and interfacial film evolution, is suitable for sodium-ion half-cells or full-cells, and can improve overall stability and operating efficiency under high-voltage and long-cycle operating conditions.

The present application relates to the field of chemical pharmacy, and particularly relates to a preparation method of sertindole, comprising the following steps: taking 1-bromo-3,4-(methylenedioxy) benzene (compound A) and 4,4-dimethyl-1-penten-3-one (compound B) as raw materials, reacting the compound A with zinc powder to obtain an organic zinc reagent, and reacting the compound B with a chloro reagent to obtain a chloro compound with a terminal olefin substituted; then, the organic zinc reagent of the compound A and the chloro compound of the compound B are coupled to obtain an intermediate compound C; finally, the compound C is reduced to obtain sertindole.

In one aspect, the present disclosure provides a method of synthesis for methylone HCl, with 3,4-methylenedioxypropiophenone (MDP) as the starting material. In another aspect, the present disclosure provides stereoisomers of methylone. In another aspect, the present disclosure provides phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described prodrug form allows slow / sustained / controlled delivery of the parent phenethylamines or cathinones into the blood system in a manner that would increase the duration of therapeutic efficacy.

The invention relates to medical uses of a compound of general formula (I), (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2, which can be the same group or a different group, are independently a hydroxy group or a methoxy group or, taken together, a methylenedioxy group, R3 and R4, which can be the same group or a different group, are independently a hydroxy group or a methoxy group, R5 is phenyl group, and R6 is a phenyl group, wherein said phenyl groups are independently optionally substituted, and wherein n is 2, and to pharmaceutical compositions comprising said compound of general formula (I), for use in the treatment of cancer in a human subject, wherein said compound of general formula (I) is administered in a therapeutically effective dose to said human subject. The invention is also related to medical uses of pharmaceutical compositions comprising said compound of general formula (I) or said pharmaceutically acceptable salt thereof.

The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side chain.